Stifel analyst Daniel Arias reiterated a Buy rating and $130.00 price target on Guardant Health (NASDAQ: GH).

The analyst commented, "We checked in with two of our KOL's in the Gastro/CRC screening space to get a quick take on the updated recommendation and verbiage from the ACS. Comments are positive, with the pathway to better coverage seen as meaningful. Some concern was noted when it comes to making sure physicians understand Shield's detection limitations, but the view was that PCPs should see Shield inclusion in guidelines as a step towards more screening being done. Short quotes for some additional color from the two docs are in our full note."

For an analyst ratings summary and ratings history on Guardant Health click here. For more ratings news on Guardant Health click here.

Shares of Guardant Health closed at $127.51 yesterday.